In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...

All doses of the diabetes and weight management injectable tirzepatide (Mounjaro, Zepbound) were taken off the FDA's shortage ...

The UK Government has signed a collaboration agreement with Lilly, the pharmaceutical giant behind weight loss medication ...

The FDA resolved the shortage of Eli Lilly's tirzepatide, but may revisit allowing compounding pharmacies to make copies, ...

The reconsideration follows an Oct. 11 lawsuit that prompted U.S. District Judge Mark Pittman to temporarily halt legal proceedings to give the FDA time to reassess its ruling.

Some patients fear that they’ll lose access to tirzepatide because the US Food and Drug Administration determined that a ...

Mounjaro, the brand name for tirzepatide, is a drug that treats type 2 diabetes by lowering blood sugar levels. According to ...

In this randomized controlled trial, in patients with both moderate-severe obstructive sleep apnea (OSA) and obesity, it was ...

Mounjaro and Zepbound are now out of shortage. This should be good news—but because so many patients are taking compounded ...

A rapid-fire reversal from the Food and Drug Administration has injected even more uncertainty into what was already a wild ...

As with any new drug, parents and doctors may worry that the use of GLP-1 weight-loss meds by children and teens might ...

Now that the Mounjaro and Zepbound shortage is over, Eli Lilly is going after the cottage industry selling “compounded” ...